Challenges in the development of combination vaccines

Advances in Experimental Medicine and Biology

Volumn 397, Issue , 1996, Pages 127-132

  Ellis, Ronald W ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

ANTIBODY RESPONSE; ANTIGEN PRESENTATION; CONFERENCE PAPER; COST BENEFIT ANALYSIS; DRUG DESIGN; DRUG MARKETING; HUMAN; IMMUNIZATION; IMMUNOGENICITY; PRIORITY JOURNAL; VACCINATION; VIRUS REPLICATION;

EID: 0030065202     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4899-1382-1_17     Document Type: Article

References (14)

1. Allison, A.C., and Byars, N.E., 1992, Immunological adjuvants and their mode of action. In R. W. Ellis (ed.), Vaccines: New approaches to immunological problems. Stoneham, MA. Butterworth Publishers, 431-449.
2. Avendana, A., Ferreccia, C., Lagos, R., et al. Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine does not depress serologic responses to diphtheria, tetanus or pertussis antigens when coadministered in the same syringe with diphtheria-tetanus-pertussis vaccine at two, four and six months of age, Pediatr Infect Dis J, 1993, 12:638-643.
3. Calandra, G.B., and West, D.J. Recommendations for prevention of hepatitis B with vaccine. In R.W. Ellis (ed.), Hepatitis B vaccines in clinical practice. New York: Marcel Dekker, 1993, 1-16.
4. Dennehy, P.H., Saracen, C.L., and Peter, G. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection, Pediatrics, 1994, 94: 514-516.
5. Giebing, P.G., Hall, C.B., and Plotkin, S.A. (eds.). Reports of the Committee on Infectious Diseases, 20th ed. Elk Grove Village, IL: American Academy of Pediatrics, 1986.
6. Paradiso, P.R., Hogerman, D. A., Madore, D.V., et al. Safety and immunogenicity of a combined diphtheria, tetanus, pertussis and Haemophilus influenzae type b vaccine in young infants, Pediatrics, 1993, 92: 827-832.
7. Sawyer, L.A., McInnis, J., Patel, A., et al. Deleterious effect of thimerosal on the potency of inactivated poliovirus vaccine, Vaccine , 1994, 12: 851-856.
8. Shapiro, E.D., Berg, A.T., Austrian, R., et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine, New Eng J Med, 1991, 325, 1453-1460.
9. Stevens, C.E., Taylor, P.E., Tong, M.J., et al. Yeast-recombinant hepatitis B vaccine: Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission, JAMA, 1987, 257, 2612-2616.
10. Szmuness, W., Stevens, C.E., Zang, E.A., et al. Controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): A final report, Hepatology, 1981, 1, 377-385.
11. Takahashi, M., Okuno, Y. Otsuka, T., et al. , Development of a live attenuated varicella vaccine. Biken, 1975, 18, 25-33.
12. Watemberg, N., Dagan, R., Arbelli, Y., et al. Safety and immunogenicity of Haemophilus influenzae type b-tetanus protein conjugate vaccine, mixed in the same syringe with diphtheria-tetanus-pertussis vaccine in young infants, Pediatr Infect Dis J, 1991, 10, 758-763.
13. Weibel, R.E., Buynak, E.B., McLean, A.A., et al. Follow-up surveillance for antibody in human subjects following live attenuated measles, mumps and rubella virus vaccines. Proc Soc Exp Biol Med, 1979, 162: 328.
14. World Health Organization, Weekly Epidemiological Record, April 7, 1995, pp. 97-101.